EuroTARGET: European collaborative project on TArgeted therapy in Renal cell cancer: GEnetic and Tumour-related biomarkers for response and toxicity
Phase 4
Recruiting
- Conditions
- metastatic renal cell cancer - metastatic kidney cancer10038364
- Registration Number
- NL-OMON34570
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 600
Inclusion Criteria
Adult patients with metastatic kidney cancer
Exclusion Criteria
Unable to read and understand the informed consent forms
Age under 18
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Therapy response:<br /><br>- poor responders defined as: no response after initiation of treatment (i.e.,<br /><br>continued progressive disease) evaluated by RECIST criteria (see<br /><br>http://www.recist.com/).<br /><br>- good responders: best responders (evaluated by RECIST criteria) in the<br /><br>retrospective and prospective cohorts. I.e., we will select the most extreme<br /><br>cases for this evaluation.<br /><br></p><br>
- Secondary Outcome Measures
Name Time Method <p>Therapy toxicity according to Common Terminology Criteria for Adverse Events<br /><br>(CTCAE) </p><br>